{
    "1": {
        "question": "What was the primary aim of the study?",
        "options": [
            "A. To compare all available antithrombotic strategies for NVAF.",
            "B. To investigate the difference in one-year outcomes after stroke between patients treated with OAC + antiplatelet and OAC only in patients with NVAF and systemic atherosclerosis.",
            "C. To evaluate the effectiveness of different statins in stroke prevention.",
            "D. To determine the bleeding risk associated with the use of DOAC alone.",
            "E. To analyze the effect of cerebral stenting on mortality rates.",
            "F. I don't know."
        ]
    },
    "2": {
        "question": "How many patients were treated with OAC + antiplatelet?",
        "options": [
            "A. 149",
            "B. 296",
            "C. 233",
            "D. 449",
            "E. 112",
            "F. I don't know."
        ]
    },
    "3": {
        "question": "What was the hazard ratio for all-cause mortality in patients receiving OAC + antiplatelet after inverse probability of treatment weighting?",
        "options": [
            "A. 1.48",
            "B. 0.48",
            "C. 2.76",
            "D. 0.63",
            "E. 3.00",
            "F. I don't know."
        ]
    },
    "4": {
        "question": "What percentage of patients in the study had atherosclerotic lesions in one arterial bed?",
        "options": [
            "A. 95.9%",
            "B. 65.8%",
            "C. 33.5%",
            "D. 27.2%",
            "E. 6.1%",
            "F. I don't know."
        ]
    },
    "5": {
        "question": "Which antiplatelet was most frequently prescribed in the study?",
        "options": [
            "A. Cilostazol",
            "B. Triflusal",
            "C. Aspirin",
            "D. Prasugrel",
            "E. Aggrenox",
            "F. I don't know."
        ]
    },
    "6": {
        "question": "According to the study, which group showed a higher risk of recurrent ischemic stroke?",
        "options": [
            "A. Patients on statins only",
            "B. Patients on OAC alone",
            "C. Patients on OAC + antiplatelet",
            "D. Patients with hypertension",
            "E. Patients with coronary stents",
            "F. I don't know."
        ]
    },
    "7": {
        "question": "What was the main limitation of the study according to the authors?",
        "options": [
            "A. Lack of a control group",
            "B. Limited follow-up duration",
            "C. Small sample size",
            "D. Potential selection bias due to retrospective nature",
            "E. Inadequate statistical methods",
            "F. I don't know."
        ]
    },
    "8": {
        "question": "What percentage of patients received a single antiplatelet agent in the OAC + antiplatelet group?",
        "options": [
            "A. 50%",
            "B. 75%",
            "C. 90%",
            "D. 96.6%",
            "E. 80%",
            "F. I don't know."
        ]
    },
    "9": {
        "question": "What was the effect of combined OAC and antiplatelet therapy on myocardial infarction risk according to inverse probability of treatment weighting?",
        "options": [
            "A. No effect",
            "B. Increased risk",
            "C. Decreased risk",
            "D. Only effective in patients over age 75",
            "E. Not evaluated",
            "F. I don't know."
        ]
    },
    "10": {
        "question": "Which factor was identified as an independent determinant for the use of OAC + antiplatelet in multivariable logistic regression analysis?",
        "options": [
            "A. Age",
            "B. Sex",
            "C. CAOD",
            "D. Dyslipidemia",
            "E. Smoking",
            "F. I don't know."
        ]
    },
    "11": {
        "question": "Among patients receiving OAC alone, what percentage received DOAC?",
        "options": [
            "A. 45.0%",
            "B. 65.2%",
            "C. 34.8%",
            "D. 55.0%",
            "E. 30.0%",
            "F. I don't know."
        ]
    },
    "12": {
        "question": "What was the study design?",
        "options": [
            "A. Double-blind randomized trial",
            "B. Retrospective cohort study",
            "C. Prospective cohort study",
            "D. Cross-sectional study",
            "E. Case-control study",
            "F. I don't know."
        ]
    },
    "13": {
        "question": "What proportion of patients in the study had cerebral atherosclerosis?",
        "options": [
            "A. 62.5%",
            "B. 16.6%",
            "C. 43.4%",
            "D. 27.2%",
            "E. 9.9%",
            "F. I don't know."
        ]
    },
    "14": {
        "question": "Which statistical analysis was used to balance baseline characteristics in this study?",
        "options": [
            "A. Multiple linear regression",
            "B. Pearson\u2019s chi-square test",
            "C. Kaplan-Meier survival analysis",
            "D. Inverse probability of treatment weighting",
            "E. Log-rank test",
            "F. I don't know."
        ]
    },
    "15": {
        "question": "Which outcome showed a significant difference after matching: all-cause mortality, myocardial infarction, or hemorrhagic stroke?",
        "options": [
            "A. Myocardial infarction",
            "B. All-cause mortality",
            "C. Hemorrhagic stroke",
            "D. Bleeding events",
            "E. No significant differences were observed",
            "F. I don't know."
        ]
    },
    "16": {
        "question": "What percentage of patients included in the study were male?",
        "options": [
            "A. 43.5%",
            "B. 67.8%",
            "C. 59.3%",
            "D. 75.4%",
            "E. 50%",
            "F. I don't know."
        ]
    },
    "17": {
        "question": "What were the two most common antiplatelet agents used?",
        "options": [
            "A. Aspirin and Clopidogrel",
            "B. Triflusal and Cilostazol",
            "C. Prasugrel and Ticlopidine",
            "D. Aggrenox and Triflusal",
            "E. Clopidogrel and Aggrenox",
            "F. I don't know."
        ]
    },
    "18": {
        "question": "What was the primary outcome of the study?",
        "options": [
            "A. Rate of statin prescription",
            "B. Bleeding events",
            "C. All-composite outcome within 1 year after the index stroke",
            "D. Hypertension control",
            "E. Measurement of NIHSS scores",
            "F. I don't know."
        ]
    },
    "19": {
        "question": "For which subgroup did interactions affect the efficacy of OAC + antiplatelet treatment?",
        "options": [
            "A. Patients with low GFR",
            "B. Patients with aortic atheroma",
            "C. Patients with cerebral or coronary stents or hypertension",
            "D. Current smokers",
            "E. Female patients",
            "F. I don't know."
        ]
    },
    "20": {
        "question": "What percentage of patients were on OAC alone?",
        "options": [
            "A. 66.5%",
            "B. 43.4%",
            "C. 33.5%",
            "D. 22.1%",
            "E. 15.1%",
            "F. I don't know."
        ]
    },
    "21": {
        "question": "How many patients had more than two causes as the most common stroke subtype etiology?",
        "options": [
            "A. 20.9%",
            "B. 10.9%",
            "C. 65.8%",
            "D. Cannot be determined from the article",
            "E. 81.6%",
            "F. I don't know."
        ]
    },
    "22": {
        "question": "Which outcome had a P-value indicating statistical significance after inverse probability treatment weighting for ischemic stroke?",
        "options": [
            "A. 0.750",
            "B. 0.123",
            "C. 0.045",
            "D. 0.044",
            "E. 0.982",
            "F. I don't know."
        ]
    },
    "23": {
        "question": "What was the percentage of patients who had two atherosclerotic beds affected?",
        "options": [
            "A. 6.1%",
            "B. 27.2%",
            "C. 65.8%",
            "D. 33.5%",
            "E. 9.9%",
            "F. I don't know."
        ]
    },
    "24": {
        "question": "What method was used to calculate estimated glomerular filtration rates in the study?",
        "options": [
            "A. Cockcroft\u2013Gault method",
            "B. MDRD study formula",
            "C. CKD-EPI method",
            "D. Inulin clearance test",
            "E. None of the above",
            "F. I don't know."
        ]
    },
    "25": {
        "question": "What is the significance of the Cox regression analysis reported in the study?",
        "options": [
            "A. It showed higher bleeding risks for OAC alone.",
            "B. It indicated higher all-cause mortality in the OAC alone group.",
            "C. It determined the most effective anticoagulant.",
            "D. It calculated the prevalence of cerebral atherosclerosis.",
            "E. It showed a higher risk of myocardial infarction for combined treatment.",
            "F. I don't know."
        ]
    },
    "26": {
        "question": "Which statistical software was used for the analysis in the study?",
        "options": [
            "A. SPSS",
            "B. MATLAB",
            "C. R",
            "D. Python",
            "E. SAS",
            "F. I don't know."
        ]
    },
    "27": {
        "question": "What is the correct interpretation for the hazard ratio of 0.48 for all-cause mortality after balancing characteristics?",
        "options": [
            "A. There is no effect on mortality when using combined treatment.",
            "B. There is a 52% reduction in risk of mortality with OAC + antiplatelet.",
            "C. There is a 48% increase in risk of mortality when using OAC alone.",
            "D. The hazard ratio indicates increased bleeding risk.",
            "E. It signifies the same mortality risk between groups.",
            "F. I don't know."
        ]
    },
    "28": {
        "question": "What does 'inverse probability of treatment weighting' refer to in this study?",
        "options": [
            "A. A method to calculate the number of recurrent events",
            "B. A technique to adjust for selection bias in observational studies",
            "C. A measure of drug efficacy",
            "D. An approach to randomize patients",
            "E. A ranking procedure for major risk factors",
            "F. I don't know."
        ]
    },
    "29": {
        "question": "What role does hypertension play according to the study's findings?",
        "options": [
            "A. Increases the risk of myocardial infarction only",
            "B. Is unrelated to treatment outcomes",
            "C. Interacts with antithrombotic type affecting outcomes",
            "D. Determines the need for anticoagulation",
            "E. Has no significant effect on mortality",
            "F. I don't know."
        ]
    },
    "30": {
        "question": "What percentage of patients were on anticoagulation, according to the study's exclusion criteria?",
        "options": [
            "A. 83.5%",
            "B. 57.7%",
            "C. 40.3%",
            "D. 33.5%",
            "E. 100%",
            "F. I don't know."
        ]
    },
    "31": {
        "question": "What was the reported impact of combining OAC and antiplatelet on bleeding events?",
        "options": [
            "A. Significantly reduced",
            "B. Significantly increased",
            "C. No significant difference",
            "D. Only increased in patients with CHD",
            "E. Reduced compared to VKA alone",
            "F. I don't know."
        ]
    },
    "32": {
        "question": "What fuelled the need for an optimum antithrombotic strategy in patients with NVAF and systemic atherosclerosis?",
        "options": [
            "A. Reduced prevalence of CAOD",
            "B. High bleeding risk of VKA",
            "C. Co-existence of vascular lesions increasing event risks",
            "D. Lack of effective antithrombotic drugs",
            "E. High cost of treatment",
            "F. I don't know."
        ]
    },
    "33": {
        "question": "How does the study suggest recurrent ischemic strokes be managed in patients with NVAF and atherosclerosis?",
        "options": [
            "A. Increase DOAC dosage",
            "B. Implement stricter vascular risk control",
            "C. Add a second antiplatelet agent",
            "D. Discontinue anticoagulation",
            "E. Prescribe higher statin doses",
            "F. I don't know."
        ]
    },
    "34": {
        "question": "How many patients had PAOD as per the study data?",
        "options": [
            "A. 13",
            "B. 74",
            "C. 193",
            "D. 278",
            "E. 62",
            "F. I don't know."
        ]
    },
    "35": {
        "question": "How frequent was transesophageal echocardiography performed according to the article?",
        "options": [
            "A. 70.5%",
            "B. 63.4%",
            "C. 35.5%",
            "D. 80.3%",
            "E. All patients",
            "F. I don't know."
        ]
    },
    "36": {
        "question": "Which event was most common as a recurrent ischemic stroke outcome?",
        "options": [
            "A. No incidents",
            "B. Fatal recurrent ischemic stroke",
            "C. Non-fatal recurrent ischemic stroke",
            "D. Increase in mortality rate",
            "E. Frequent hospitalization due to recurrence",
            "F. I don't know."
        ]
    },
    "37": {
        "question": "What percentage of enrolled patients were current smokers?",
        "options": [
            "A. 14.8%",
            "B. 22.7%",
            "C. 11.3%",
            "D. 6.7%",
            "E. 19.9%",
            "F. I don't know."
        ]
    },
    "38": {
        "question": "Which subgroup analysis indicated consistent benefits for OAC + antiplatelet treatment?",
        "options": [
            "A. Patients with cerebral atheroma",
            "B. Patients with no stents",
            "C. Patients without hypertension",
            "D. Female patients",
            "E. Patients under 75 years old",
            "F. I don't know."
        ]
    },
    "39": {
        "question": "According to the study, what factors may have affected medication efficacy?",
        "options": [
            "A. Study size",
            "B. Patient characteristics or comorbidities",
            "C. Result dissemination delay",
            "D. Side effects of drugs",
            "E. Geographical location",
            "F. I don't know."
        ]
    },
    "40": {
        "question": "Which echocardiography method was a routine examination unless not performed due to conditions?",
        "options": [
            "A. Transthoracic echocardiography",
            "B. Stress echocardiography",
            "C. Transesophageal echocardiography",
            "D. Dobutamine stress echocardiography",
            "E. 3D Echocardiography",
            "F. I don't know."
        ]
    },
    "41": {
        "question": "Which was the most common site of systemic atherosclerosis among study patients?",
        "options": [
            "A. Peripheral arteries",
            "B. Cerebral arteries",
            "C. Coronary arteries",
            "D. Renal arteries",
            "E. Abdominal aorta",
            "F. I don't know."
        ]
    },
    "42": {
        "question": "What percentage of patients had a coronary stent according to baseline characteristics?",
        "options": [
            "A. 13.9%",
            "B. 3.4%",
            "C. 29.5%",
            "D. 6.1%",
            "E. 47.0%",
            "F. I don't know."
        ]
    },
    "43": {
        "question": "Which treatment group had more patients with hypertension?",
        "options": [
            "A. The study didn't assess hypertension",
            "B. OAC alone group",
            "C. OAC + antiplatelet group",
            "D. DOAC only subgroup",
            "E. VKA only subgroup",
            "F. I don't know."
        ]
    },
    "44": {
        "question": "What was the most common etiology determined according to TOAST classification?",
        "options": [
            "A. Large artery atherosclerosis",
            "B. Cardioembolism",
            "C. Small vessel occlusion",
            "D. Multiple causes",
            "E. Undetermined causes",
            "F. I don't know."
        ]
    },
    "45": {
        "question": "Why couldn't the study evaluate the intensity of OAC during follow-up?",
        "options": [
            "A. Lack of interest",
            "B. Technical challenges in measurement",
            "C. Incomplete data and variable patient compliance",
            "D. The evaluation was deemed unnecessary",
            "E. Other anticoagulants were not monitored",
            "F. I don't know."
        ]
    },
    "46": {
        "question": "Which figure in the article presents Kaplan-Meier survival curves?",
        "options": [
            "A. Figure 2",
            "B. Figure 3",
            "C. Figure 1",
            "D. Figure 4",
            "E. There were no figures with survival curves",
            "F. I don't know."
        ]
    },
    "47": {
        "question": "Which cohort was used for this study?",
        "options": [
            "A. Multi-center international cohort",
            "B. Single hospital-based observational cohort",
            "C. Multi-center randomized controlled trial group",
            "D. Single-city matched trial",
            "E. Internet-based patient self-reporting study",
            "F. I don't know."
        ]
    },
    "48": {
        "question": "What clinical trial registration number was indicated for the study?",
        "options": [
            "A. NCT01245934",
            "B. NCT03510312",
            "C. NCT05673813",
            "D. NCT07896324",
            "E. Not registered",
            "F. I don't know."
        ]
    },
    "49": {
        "question": "What was the result of bleeding complication analysis for OAC combined with antiplatelet?",
        "options": [
            "A. Higher than OAC alone",
            "B. Higher in patients with OAC + aspirin combination",
            "C. Significant only for gastrointestinal bleeding",
            "D. No significant difference compared to OAC alone",
            "E. Exclusively higher with dual antiplatelet plus OAC",
            "F. I don't know."
        ]
    },
    "50": {
        "question": "In the article, what was the reported effect size for the myocardial infarction hazard with OAC + antiplatelet after adjustment?",
        "options": [
            "A. HR 2.19",
            "B. HR 0.00",
            "C. HR 5.99",
            "D. HR 1.12",
            "E. HR 0.91",
            "F. I don't know."
        ]
    }
}